- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Sunrest Lifescience has announced a board meeting approving the consolidated financial results for the half year and year ended March 31, 2025. Revenue stood at ₹33.12 Cr with profit before tax surging to ₹2.61 Cr from last year’s ₹0.59 Cr. Positive operational cash flow of ₹1.43 Cr funded ₹1.37 Cr in property and equipment investments. Long-term borrowings are ₹5.73 Cr, while trade receivables remain high at ₹36.37 Cr. Audit concluded with a clean opinion. No dividends or capital raising plans were disclosed.